On May 3 this year, a secret genomic ‘moon-shot’ project begun.
Its goals…and the visionaries behind it…make even Elon Musk’s plans for a tunnel under LA look lame and boring.
This project, if the research I’ve compiled on it is even half correct, is going to change medicine more than anything since the discovery of antibiotics.
It could make four current no-name companies blue chip sensations in the next decade.
The central driver behind it all is blockchain
But it’s only now dawning that cryptos were something of a red herring when it comes to blockchain.
So far, we’ve seen banks and investment companies leap on the tech and its potential to reshape finance.
Silicon Valley behemoths like IBM, Amazon, and Microsoft have started shunting huge money at researching ways to integrate blockchain in their models.
But, as we’ve been covering all week, I believe the industry that could be MOST disrupted by blockchain is ALSO the one where the link is the least researched.
And that’s biotech.
Figure out how these two things are going to collide over the next five years — and the stocks that might explode because of this collision — and, if you’re right, you could be looking at exponential 1,000% to 30,000% potential gains.
I have four such stocks I’ve been forensically taking apart in recent months.
I’m going to showcase each one for you next week.
But let’s just circle back to those three words: ‘if you’re right’.
We’re still at the very early stages of the blockchain revolution.
That’s where the biggest gains are potentially on the table.
But it’s also the point where your assumptions about the future could be proven wrong…or even look laughable…in five years’ time.
In a 1998 issue of BYTE Magazine, for instance, Edmund DeJesus made the claim that ‘(Y2K) is a crisis without precedent in human history.’
The inventor of Ethernet, Robert Metcalfe, predicted in December 1995 that ‘the Internet will soon go spectacularly supernova and in 1996 catastrophically collapse.’
Forecasting tech step-changes can make fools out of all of us.
Even the so-called experts.
But that doesn’t mean we shouldn’t take a stab. Especially when there is a direct precedent on how things might pan out when blockchain combines with biotech: the Human Genome Project. And the stocks that soared thousands of percent on the back of it.
Blockchain and biotech 2.0
OK, let’s dig a little deeper into what blockchain actually is before we investigate its impending collision with medicine.
As Nestor Arellano writes for Biotechnology Focus:
‘Blockchain allows digital information to be distributed but not copied.
‘Think of it as giant accounting ledger which resides on the Internet. This ledger is arranged in batches of data called blocks. The blocks use cryptographic validation to link to each other
‘Each block references and identifies the previous block forming an unbroken chain. This serves as a built-in validation that cannot be tampered with.
‘Data in any given block cannot be altered without affecting succeeding blocks. Changes cannot be made with the collusion of the network members.
‘One important bonus – the blockchain is distributed. It does not exist in one place, it exists in multiple computers of members of the particular blockchain network.’
What that basically boils down to is an ‘immutable data record’. And this is something of IMMENSE importance to companies on the cutting edge of modern medicine.
As Arellano puts it:
‘This immutable record could become indispensable for validating information associated to various stages of clinical trials especially when laboratories are located in different parts of the globe.’
But my research has taken me past that…and into a tangent that could be far more game-changing…and, potentially, FAR more profitable…
BEYOND the Human Genome Project
Throughout history, certain areas of biology have undergone various revolutions.
Be it with the research of Charles Darwin in the 19th Century, or with the discovery of the double helix some 50 years ago.
Many of these revolutionary novelties are now just normal practice in the day-to-day routines of lab life. During the past decade, before this new century, another revolutionary wave appeared.
Genomic research — from the DNA of man to those of bacteria — has forever transformed some areas of biology.
The Human Genome Project, completed in 2003, started this transformation.
As you now know, I’ve been all over this since the end of last year.
And I’m utterly convinced that a new great genomic project quietly began in May this year.
And this new project — powered by blockchain — could be about to COMPLETE the transformation that the Human Genome Project started.
If I’m correct, over the next few years, you’ll see transformations in medicine that will make those we’ve seen in the last 15 years of genomics seem pretty run-of-the-mill.
These transformations will radiate and reach all the sciences that gravitate around molecular biology.
And they will speed up advances in genomic medicine EXPONENTIALLY.
As I will show you next week, when we showcase the four stocks I’ve uncovered, blockchain is the key to it all.
Data is the lifeblood of biotech research.
But the reliance on data causes huge problems.
Sourcing it. Verifying it. Adhering to crucial privacy laws.
The project I’ll introduce you to early next week is looking to solve these problems.
Specifically: it’s a moon-shot plan to create a MEGA-HUB of genomic data.
This hub, if it’s realised, will become an absolute treasure trove for medical researchers.
It will give them superpowers.
It will create a kind of Moore’s Law for medical advancement.
And, like the Human Genome Project, it could create a flash-fire boom in a certain set of biotechnology stocks.
It’s these stocks that I want to focus on for much of next week.
Blockchain technology is about to disrupt medicine — BIG TIME.
Few people see it.
And that’s why, if I’m right and you act now, you could well make some of the most potentially profitable investments in your lifetime.
What are those investments, specifically? Keep an eye on your inbox tomorrow for my new investor report!
Editor, Exponential Stock Investor